Welcome to our dedicated page for Biomerica news (Ticker: BMRA), a resource for investors and traders seeking the latest updates and insights on Biomerica stock.
Biomerica reports developments in diagnostic-guided therapies and medical diagnostic products used in point-of-care, home, physician-office and clinical laboratory settings. The company focuses on gastrointestinal and inflammatory diseases, with recurring updates around inFoods® IBS, a finger-stick blood test used to identify individual food triggers for IBS dietary guidance, and Hp Detect™/hp+detect™, an H. pylori stool antigen diagnostic.
Biomerica news also covers commercialization and regulatory activity for products such as EZ Detect™, an at-home colorectal disease screening test, along with international distribution, laboratory partnerships, reimbursement and coding updates, clinical data presentations, fiscal results and the company’s CDMO services activity.
ConsumerDirect (NASDAQ:BMRA) appointed Gary Lu, CPA as Chief Financial Officer, adding a veteran leader with 20+ years in finance, accounting, and operations.
Lu will oversee financial operations, support strategic planning, and help scale ConsumerDirect’s subscription-based business, drawing on prior CFO experience at Biomerica and roles in fintech and Fortune 500 companies.
Biomerica (Nasdaq: BMRA) announced that real-world clinical data on its inFoods® IBS diagnostic-guided therapy was accepted for poster presentation at Digestive Disease Week (DDW) 2026, May 2–5 in Chicago.
The poster, presented by investigators from Michigan Medicine and Cleveland Clinic, follows a June 2025 randomized trial in Gastroenterology; DDW embargoed data release begins 12:01 a.m. CDT on the presentation day.
Biomerica (NASDAQ: BMRA) announced that the Medicare Administrative Contractor confirmed inFoods® IBS claims can be reviewed on an individual, claim-by-claim basis, opening a Medicare billing pathway. The test has a dedicated PLA CPT code effective Oct 1, 2025 and a CMS national payment rate of $300 for dates of service on or after Jan 1, 2026.
The company and its CLIA-certified lab partner say properly documented claims with medical necessity and diagnosis codes are positioned for payment, supported by a Level 1 randomized trial published in Gastroenterology.
Biomerica (Nasdaq: BMRA) launched its inFoods® IBS platform in Canada on April 14, 2026, via exclusive distribution by Phoenix Airmid Biomedical and certified lab processing by CanAlt Health Labs.
The launch is the company’s first commercial entry into Canada, targeting an estimated ~18% prevalence (up to 5 million Canadians) and aims to expand access to a clinically validated, non‑pharmaceutical diagnostic‑guided therapy.
Biomerica (Nasdaq: BMRA) reported third quarter fiscal 2026 results for the period ended February 28, 2026, highlighting commercial progress and cost discipline. Key items: CMS set a $300 national Medicare payment rate for inFoods® IBS effective Jan 1, 2026; European revenue rose 45% in the quarter; R&D expenses fell 24% YTD.
Q3 net sales were $0.99M versus $1.12M a year earlier; Q3 net loss was $1.31M. Management cited transition to higher-margin diagnostics and CDMO services as drivers of future margin expansion.
Biomerica (Nasdaq: BMRA) received its first commercial order for Hp Detect™, a stool antigen test for Helicobacter pylori, from one of Europe’s largest clinical laboratory chains. The initial order targets the United Kingdom, where Hp Detect™ gained MHRA registration in February 2026.
Company says the account is a strategic reference customer with potential for recurring orders and wider EU distribution as Hp Detect™ is integrated into routine testing workflows, supported by NHS UK guidance recommending H. pylori testing for dyspepsia patients.
Biomerica (Nasdaq: BMRA) received MHRA registration on March 5, 2026 for its hp+detect™ diagnostic test, authorizing commercial sales in Great Britain.
The test detects Helicobacter pylori; the company is in active discussions with UK partners to access diagnostic labs and will provide updates as agreements are finalized.
Biomerica (Nasdaq: BMRA) reported real-world responder results for inFoods® IBS: 59.4% of 69 patients had ≥30% abdominal pain reduction and 68.1% had ≥30% bloating reduction using the FDA-recognized responder endpoint.
Mean pain scores fell 34.6% and bloating 41.7% at 8 weeks. Commercial milestones include a $300 national Medicare rate (effective Jan 1, 2026), a dedicated CPT PLA code (effective Oct 1, 2025), and a Henry Schein marketing services agreement.
Biomerica (Nasdaq: BMRA) announced that Vietnam’s Hanoi Department of Health approved EZ Detect™ for nationwide sales and distribution on Feb 18, 2026. The FDA-cleared, two-minute at-home colorectal screening test will be sold via a major distributor across pharmacies, hospitals, clinics, and online channels.
The approval targets Vietnam’s high unmet need: 16,835 new colorectal cancer cases in 2022 and a reported 45% five-year survival rate, versus 91% when detected early in the US.
Biomerica (Nasdaq: BMRA) reported Q2 fiscal 2026 results for the period ended November 30, 2025. Q2 revenue was $1.21M versus $1.64M year-ago and six-month revenue was $2.59M versus $3.44M prior year. Management highlighted a strategic pivot to higher-margin diagnostic-guided therapy products and cost discipline. Working capital improved 14.7% (about $457k) and cash increased to $2.5M. CMS later established a $300 Medicare payment rate for inFoods IBS effective January 1, 2026. Operating expenses declined year-to-date and R&D spending was reduced by 27% as the company reallocates resources to commercialization.